? Renal pelvis cancer is a tumor that occurs in the epithelium of the renal pelvis or calyces. Most are transitional cell carcinomas, and a few are squamous cell carcinomas and adenocarcinomas. The latter two account for about 15% of renal pelvis cancers. Their malignancy is much higher than that of transitional cell carcinoma. high. The diagnosis and treatment should be regarded as a whole, and a local transitional cell carcinoma cannot be treated in isolation. Treatment for renal pelvis cancer will mainly focus on surgery in the early stage. So, can you sit back and relax after surgery for renal pelvis cancer? ? In surgery for renal pelvis cancer, the diseased kidney and the entire ureter, including part of the bladder next to the ureteral opening, are generally removed to prevent the recurrence of tumors in the remaining ureter. The prognosis of renal pelvis tumors is closely related to the degree of cell differentiation and pathological staging. The 5-year survival rate of G1 grade is 75%, the 5-year survival rate of G2 grade is 55%, and the 5-year survival rate of G3 grade is 27%. Squamous cell carcinoma and adenocarcinoma have a poor prognosis, with a 5-year survival rate of 0. Secondly, when the contralateral renal function is impaired or the nephrectomy has been performed, local resection of pedunculated papillary tumors with well-differentiated cells and no infiltration on biopsy can be performed. Individual small renal pelvic tumors can also be removed by endoscopic surgery or electrocautery coagulation. The addition of postoperative radiotherapy has a certain effect on improving survival rate. ? How long is the survival period? Generally related to the differentiation of renal pelvis cancer, the differentiation of cancer cells and the degree of basal invasion vary greatly, and the prognosis is also very different. For renal pelvis tumors that are well differentiated and have no infiltration, the 5-year survival rate after surgery is over 60%. However, the survival rate after surgery for renal pelvis cancer is generally lower than that for kidney cancer. The prognosis of renal pelvis tumors is closely related to the degree of cell differentiation and pathological staging. The 5-year survival rate of G1 grade is 75%, the 5-year survival rate of G2 grade is 55%, and the 5-year survival rate of G3 grade is 27%. Squamous cell carcinoma and adenocarcinoma have a poor prognosis, with a 5-year survival rate of 0. The survival period after early-stage surgery for renal pelvis cancer is closely related to its treatment. It is very important to use biological immunotherapy. Biological immunotherapy for renal pelvis cancer is to adjust the body's internal environment, enhance immune function, and effectively prevent recurrence and metastasis.

(Editor: Lin Dan)